C22 Galactosylceramide-d4 (d18:1/22:0-d4) (Synonyms: Galactosylceramide-d4 (d18:1/22:0-d4), N-Docosanoyl-β-D-Galactosylceramide-d4, GalCer(d18:1/22:0-d4)) |
| Katalog-Nr.GC46998 |
A neuropeptide with diverse biological activities
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: N/A
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
C22 Galactosylceramide-d4 is intended for use as an internal standard for the quantification of C22 galactosylceramide by GC- or LC-MS. C22 Galactosylceramide is a sphingolipid that has been found in the central nervous system.1,2 C22 Galactosylceramide levels are increased in the spinal cord, but not the brain or liver, of mice fed a methionine-restricted diet.1 C22 Galactosylceramide has been found in postmortem hippocampus from patients with Alzheimer's disease.2 [Matreya, LLC.]
1.JovÉ, M., Ayala, V., RamÍrez-NÚÑez, O., et al.Specific lipidome signatures in central nervous system from methionine-restricted miceJ. Proteome Res.12(6)2679-2689(2013) 2.Hejazi, L., Wong, J.W.H., Cheng, D., et al.Mass and relative elution time profiling: Two-dimensional analysis of sphingolipids in Alzheimer's disease brainsBiochem. J.438(1)165-175(2011)
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *